NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, a first-in-class intranasal antiviral designed to provide broad protection against respiratory viruses at the point of entry. Our simple, preventative host-directed approach has been shown to protect against influenza in
Location: United States
Total raised: $34M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.06.2026 | - | $34M | RA Capital... |
Mentions in press and media 4
| Date | Title | Description |
| 30.06.2026 | NorthLinks Bio Debuts With $34M For Broad-Spectrum Antiviral | NorthLinks Bio emerges with $34M funding from RA Capital. The clinical-stage biotech focuses on broad-spectrum antiviral preventatives. Its lead, intranasal HEX17, targets respiratory viral entry. HEX17 completed Phase 2a, demonstrating a 5... |
| 25.06.2026 | NorthLinks Bio Launches With $34 Million Financing | NorthLinks Bio announced its launch and the completion of a $34 million financing from RA Capital Management. NorthLinks Bio is a clinical-stage biotechnology company developing broad-spectrum antiviral preventive medicines for respiratory ... |
| 23.06.2026 | NorthLinks Bio Secures $34M in Funding | NorthLinks Bio, a Boston, Massachusetts-based and Scottish-founded clinical-stage biotechnology company developing broad-spectrum antiviral preventative medicines, officially launched after securing $34m in funding. RA Capital Management ma... |
| - | NorthLinks Bio | “NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, a first-in-class intranasal antiviral designed to provide broad protection against respiratory viruses at the point of entry. Our simple, preventative approach ... |